Superworth

Cytokinetics price to free cash flow CYTK

Market value divided by free cash flow over the last twelve months, since 2015.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
68.2×
Nov 2017
Peer median
46.0×

Cytokinetics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Nov 2017, at 68.2×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
201768.2×13.5×77.8×
201674.6×43.2×78.2×
201566.7×35.8×76.7×

Against its peers

Companies in Drug Manufacturers - General nearest Cytokinetics' size, closest first, today.

CompanyPrice to free cash flow
CYTKCytokineticsn/m
TGTXTG Therapeutics477×
PTGXProtagonist Therapeutics68.6×
CORTCorcept Therapeutics86.8×
ALKSAlkermes plc.33.0×
BMRNBiomarin Pharmaceutical14.7×
AMRXAmneal Pharmaceuticals50.9×
LGNDLigand Pharmaceuticals46.0×
KNSAKiniksa Pharmaceuticals International32.7×
JAZZJazz Pharmaceuticals8.7×
INDVIndivior Pharmaceuticalsn/m
Peer median46.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Cytokinetics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.